Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (Wuhan University), Ministry of Education and Wuhan University School of Pharmaceutical Sciences, 185 East Lake Road, Wuhan, 430071, People's Republic of China.
Appl Microbiol Biotechnol. 2015 Dec;99(24):10575-85. doi: 10.1007/s00253-015-6931-4. Epub 2015 Aug 29.
The current diminishing returns in finding useful antibiotics and the occurrence of drug-resistant bacteria call for the need to find new antibiotics. Moreover, the whole genome sequencing revealed that the biosynthetic potential of Streptomyces, which has produced the highest numbers of approved and clinical-trial drugs, has been greatly underestimated. Considering the known gene editing toolkits were arduous and inefficient, novel and efficient gene editing system are desirable. Here, we developed an engineered CRISPR/Cas9 (clustered regularly interspaced short palindromic repeat/CRISPR-associated protein) combined with the counterselection system CodA(sm), the D314A mutant of cytosine deaminase, to rapidly and effectively edit Streptomyces genomes. In-frame deletion of the actinorhodin polyketide chain length factor gene actI-ORF2 was created in Streptomyces coelicolor M145 as an illustration. This CRISPR/Cas9-CodA(sm) combined system strikingly increased the frequency of unmarked mutants and shortened the time required to generate them. We foresee the system becoming a routine laboratory technique for genome editing to exploit the great biosynthetic potential of Streptomyces and perhaps for other medically and economically important actinomycetes.
目前,发现有用抗生素的收益递减,以及耐药细菌的出现,都要求我们寻找新的抗生素。此外,全基因组测序表明,产生了最多数量批准和临床试验药物的链霉菌的生物合成潜力被大大低估了。考虑到已知的基因编辑工具包繁琐且效率低下,因此需要新型且高效的基因编辑系统。在这里,我们开发了一种工程化的 CRISPR/Cas9(成簇规律间隔短回文重复/CRISPR 相关蛋白)与反选择系统 CodA(sm),即胞嘧啶脱氨酶的 D314A 突变体相结合,以快速有效地编辑链霉菌基因组。以链霉菌天蓝色变种 M145 中放线紫红素聚酮链长因子基因 actI-ORF2 的框内缺失为例。这种 CRISPR/Cas9-CodA(sm) 联合系统显著提高了无标记突变体的频率,并缩短了生成它们所需的时间。我们预计该系统将成为用于基因组编辑的常规实验室技术,以利用链霉菌的巨大生物合成潜力,也许还可以用于其他具有医学和经济重要性的放线菌。